The incidence of obesity is increasing and represents a major public health problem worldwide. According to the World Health Organization, obesity is defined in people whose BMI is greater than 25 kg / m2. Around 2 billion people worldwide suffer from overweight or obesity. Obesity can be divided into several different types, and clinically we are most concerned about the so-called ''visceral'' obesity. A common consequence of obesity is the development of metabolic syndrome.This reffers to the set of disorders that include a disorder of body fat regulation, insulin insensitivity, high blood pressure and visceral type obesity. There are various criteria for diagnosing metabolic syndrome and its definition is not yet fully agreed. The diagnostic criteria were developed by the World Health Organization (WHO), the International Diabetes Federation (IDF) and participants in the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). In addition to significantly affecting the quality of life, metabolic syndrome significantly burdens the overall health system and is associated with the incidence of cardiovascular diseases that continue to be the leading cause of mortality and morbidity in developed countries, despite the improving treatment outcomes. That's why their timely diagnosis and prevention is of utmost importance. There are several ways to predict the development of cardiovascular diseases in the next 10 years in patients with regard to various parameters. The most clinically significant are Framingham risk tables, QRISK3 (Cardiovascular risk score), ASSIGN and SCORE2. The aim of this paper was to summarize previous knowledge and to show the connection between these three clinically extremely important entities that afflict a large number of people worldwide.